{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T14:46:42Z","timestamp":1749912402102},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s40268-013-0008-6","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T09:29:04Z","timestamp":1364462944000},"page":"43-51","source":"Crossref","is-referenced-by-count":10,"title":["Effect of Prucalopride on the Pharmacokinetics of Oral Contraceptives in Healthy Women"],"prefix":"10.1007","volume":"13","author":[{"given":"Vera","family":"Van de Velde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieve","family":"Vandeplassche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke","family":"Hoppenbrouwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Boterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannie","family":"Ausma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,29]]},"reference":[{"key":"8_CR1","unstructured":"European Medicines Agency. Resolor (prucalopride): summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001012\/WC500053998.pdf . Accessed 26 March 2012."},{"issue":"17","key":"8_CR2","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2165\/11204000-000000000-00000","volume":"69","author":"JE Frampton","year":"2009","unstructured":"Frampton JE. Prucalopride. Drugs. 2009;69(17):2463\u201376.","journal-title":"Drugs"},{"issue":"22","key":"8_CR3","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","volume":"358","author":"M Camilleri","year":"2008","unstructured":"Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344\u201354.","journal-title":"N Engl J Med"},{"issue":"3","key":"8_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2008.03884.x","volume":"29","author":"EM Quigley","year":"2009","unstructured":"Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation: a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29(3):315\u201328.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"8_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gut.2008.162404","volume":"58","author":"J Tack","year":"2009","unstructured":"Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357\u201365.","journal-title":"Gut"},{"issue":"7","key":"8_CR6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1365-2036.2008.03806.x","volume":"28","author":"A Wald","year":"2008","unstructured":"Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008;28(7):917\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"8_CR7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2982.2011.01709.x","volume":"23","author":"J Tack","year":"2011","unstructured":"Tack J, Muller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation: a European perspective. Neurogastroenterol Motil. 2011;23(8):697\u2013710.","journal-title":"Neurogastroenterol Motil"},{"issue":"11","key":"8_CR8","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/j.1572-0241.2001.05259.x","volume":"96","author":"P Pare","year":"2001","unstructured":"Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96(11):3130\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"8_CR9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1572-0241.2004.04114.x","volume":"99","author":"PD Higgins","year":"2004","unstructured":"Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99(4):750\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"11\u201312","key":"8_CR10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1365-2036.2007.03540.x","volume":"26","author":"RS Choung","year":"2007","unstructured":"Choung RS, Locke GR 3rd, Schleck CD, et al. Cumulative incidence of chronic constipation: a population-based study 1988\u20132003. Aliment Pharmacol Ther. 2007;26(11\u201312):1521\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"8_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","volume":"65","author":"P Barditch-Crovo","year":"1999","unstructured":"Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther. 1999;65(4):428\u201338.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 9","key":"8_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1289\/ehp.94102s935","volume":"102","author":"HM Bolt","year":"1994","unstructured":"Bolt HM. Interactions between clinically used drugs and oral contraceptives. Environ Health Perspect. 1994;102(Suppl 9):35\u20138.","journal-title":"Environ Health Perspect"},{"key":"8_CR13","unstructured":"European Medicines Agency. ICH harmonised tripartite guidelines for good clinical practice, 1996. http:\/\/www.emea.europa.eu\/pdfs\/human\/ich\/013595en.pdf . Accessed 11 June 2012."},{"key":"8_CR14","unstructured":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/ . Accessed 12 August 2009."},{"key":"8_CR15","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for industry: bioanalytical method validation, 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf . Accessed 14 December 2011."},{"key":"8_CR16","unstructured":"Organisation for Economic Co-operation and Development. OECD principles of good laboratory practice (GLP). http:\/\/www.oecd.org\/document\/63\/0,3746,en_2649_34377_2346175_1_1_1_1,00.html . Accessed 13 April 2012."},{"issue":"6 Pt 2","key":"8_CR17","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/0002-9378(90)90562-L","volume":"163","author":"JP Hanker","year":"1990","unstructured":"Hanker JP. Gastrointestinal disease and oral contraception. Am J Obstet Gynecol. 1990;163(6 Pt 2):2204\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"8_CR18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2036.2010.04455.x","volume":"32","author":"M Camilleri","year":"2010","unstructured":"Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation: follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010;32(9):1113\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl I","key":"8_CR19","doi-asserted-by":"crossref","first-page":"S820","DOI":"10.1016\/S0016-5085(12)63188-6","volume":"142","author":"EM Quigley","year":"2012","unstructured":"Quigley EM, Tack J, Kerstens R, et al. The efficacy and safety of oral prucalopride in female patients with chronic constipation who had failed laxative therapy (EMA-authorised population) is similar to that of the ITT population in the initial pivotal trials: pooled data analysis. Gastroenterology. 2012;142(Suppl I):S820\u20131.","journal-title":"Gastroenterology"},{"issue":"1","key":"8_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1152\/physiolgenomics.00038.2008","volume":"34","author":"JH Maeyer De","year":"2008","unstructured":"De Maeyer JH, Aerssens J, Verhasselt P, et al. Alternative splicing and exon duplication generates 10 unique porcine 5-HT 4 receptor splice variants including a functional homofusion variant. Physiol Genomics. 2008;34(1):22\u201333.","journal-title":"Physiol Genomics"},{"issue":"3","key":"8_CR21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1124\/jpet.106.101329","volume":"317","author":"JH Maeyer De","year":"2006","unstructured":"De Maeyer JH, Prins NH, Schuurkes JA, et al. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J Pharmacol Exp Ther. 2006;317(3):955\u201364.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0008-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0008-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0008-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T02:52:00Z","timestamp":1715136720000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0008-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0008-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}